Tauro-Obeticholic acid is an active metabolite of Obeticholic acid (Ocaliva; 6-ECDCA; INT747; 6-Ethylchenodeoxycholic acid) formed by conjugating with taurine, or 2-aminoethanesulfonic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist and semisynthetic bile acid analog (derivative of chenodeoxycholic acid) approved by FDA in 2016 to treat primary biliary cholangitis. Tauro-obeticholic acid is produced in vivo from obeticholic acid by taurine conjugation in the liver but can be reconverted back to obeticholic acid by intestinal microflora.

纯度：≥98%

CAS�?63239-61-6